title: Effect of inhibition of angiotensin converting enzyme and/or neutral endopeptidase on vascular and neural complications in high fat fed/low dose streptozotocin-diabetic rats.
abstract: Treating high fat fed/low dose streptozotocin-diabetic rats; model of type 2 diabetes, with ilepatril (vasopeptidase inhibitor, blocks neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE)) improved vascular and neural functions. Next, studies were performed to determine the individual effect of inhibition of NEP and ACE on diabetes-induced vascular and neural dysfunctions. High fat fed rats (8 weeks) were treated with 30 mg/kg streptozotocin (i.p.) and after 4 additional weeks, were treated for 12 weeks with ilepatril, enalapril (ACE inhibitor) or candoxatril (NEP inhibitor) followed by analysis of vascular and neural functions. Glucose clearance was impaired in diabetic rats and was not improved with treatment although treatment with ilepatril or candoxatril partially improved insulin stimulated glucose uptake by isolated soleus muscle. Diabetes caused slowing of motor and sensory nerve conduction, thermal hypoalgesia, reduction in intraepidermal nerve fiber (IENF) profiles and impairment in vascular relaxation to acetylcholine and calcitonin gene-related peptide (CGRP) in epineurial arterioles of the sciatic nerve. Inhibition of NEP improved nerve conduction velocity and inhibition of NEP or ACE improved thermal sensitivity and protected IENF density. Ilepatril and candoxatril treatments of diabetic rats were efficacious in improving vascular responsiveness to acetylcholine in epineurial arterioles; whereas all three treatments improved vascular response to CGRP. These studies suggest that inhibition of NEP and ACE activity is an effective approach for treatment of type 2 diabetes neural and vascular complications.
authors.affiliation: Department of Internal Medicine, University of Iowa, Iowa City, IA, 52246, United States.
authors.forename: Eric P
authors.initials: EP
authors.lastname: Davidson
authors.forename: Lawrence J
authors.initials: LJ
authors.lastname: Coppey
authors.forename: Amey
authors.initials: A
authors.lastname: Holmes
authors.forename: Mark A
authors.initials: MA
authors.lastname: Yorek
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001160:Arterioles / Q000187:drug effects / Q000502:physiology; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D002518:Ceramides / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000150:complications* / Q000378:metabolism / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D003929:Diabetic Neuropathies / Q000188:drug therapy*; D059305:Diet, High-Fat / Q000009:adverse effects*; D004075:Diglycerides / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005951:Glucose Tolerance Test; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D009412:Nerve Fibers / Q000187:drug effects; D009431:Neural Conduction / Q000187:drug effects; D059225:Nociception / Q000187:drug effects; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014664:Vasodilation / Q000187:drug effects
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D001786:Blood Glucose; D002518:Ceramides; D004075:Diglycerides; D017392:Thiobarbituric Acid Reactive Substances; D007703:Peptidyl-Dipeptidase A; D015260:Neprilysin